On the other hand, blocking the activation of EGFR, an antibody that selectively binds EGFR-by Cetuximab, has shown to improve the response rate of 5-Fu in patients with metastatic colorectal cancer who initially failed 5-FU-based therapy [127,128]. This evidence concerns the gene EGFR and metastatic colorectal cancer.